Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underrecognized cause of heart failure (HF). ATTR-CM can lead to a number of cardiovascular manifestations including HF, rhythm disturbances, and valvular disease that ultimately limit quality of life and prognosis. Due to advances in diagnostic modalities and therapeutic options, the prevalence of ATTR-CM is rising. There are several classes of medications under active investigation, though most therapies are most efficacious if instituted early on in the disease course. As such, early clinical recognition and prompt diagnosis are crucial to improving disease related outcomes. In this review, we highlight clinical manifestations of ATTR-CM as well as contemporary diagnostic and treatment approaches to the disease.

中文翻译：

---

转甲状腺素蛋白淀粉样变心肌病的诊治进展

转甲状腺素蛋白淀粉样心肌病 (ATTR-CM) 是心力衰竭 (HF) 的一个未被充分认识的原因。 ATTR-CM 可导致多种心血管表现，包括心力衰竭、节律紊乱和瓣膜疾病，最终限制生活质量和预后。由于诊断方式和治疗方案的进步，ATTR-CM 的患病率正在上升。有几类药物正在积极研究中，尽管大多数疗法如果在病程早期开始使用是最有效的。因此，早期临床识别和及时诊断对于改善疾病相关结果至关重要。在这篇综述中，我们重点介绍 ATTR-CM 的临床表现以及该疾病的当代诊断和治疗方法。